Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. 2017

Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.

Growing evidence shows tumor-infiltrating neutrophils (TINs) involvement in tumorigenesis. The objective of this study is to assess the prognostic effect of TINs and its impact on adjuvant chemotherapy benefits in muscle invasive bladder cancer (MIBC). A total of 142 MIBC patients from Zhongshan Hospital, 119 MIBC patients from FUSCC, and 405 MIBC patients from TCGA cohort were enrolled in the study. TINs were evaluated by immunohistochemical staining of CD66b or the CIBERSORT method. Patients with high TINs had a significantly poorer overall survival (p = 0.001, p < 0.001, and p = 0.002, respectively) in the three sets. In the multivariate analysis, the presence of high TINs (HR = 2.122, p = 0.007; HR = 3.807, p < 0.001; HR = 2.104, p = 0.001; respectively) was identified as an independent prognostic factor for overall survival in the three sets. More importantly, Low TINs patients had significantly longer overall survival in patients without ACT in the three sets. Gene set enrichment analysis showed that lymphocyte activation (p < 0.001) and T cell activation (p = 0.008) were significantly enriched in the low TINs group. In addition, TINs were negatively correlated with CD8+ T cells, suggesting that the status of high-TINs was linked to the status of immunosuppression in MIBC. TINs could be used as independent prognostic factor. Low TINs identified a subgroup of MIBC patients who appeared to benefit from adjuvant chemotherapy. Incorporation of TINs into TNM system could further stratify patients with different prognosis.

UI MeSH Term Description Entries

Related Publications

Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
July 2018, Cancer science,
Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
July 2018, Clinical cancer research : an official journal of the American Association for Cancer Research,
Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
February 2018, Annals of surgery,
Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
September 2020, The Journal of urology,
Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
September 2013, European urology,
Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
August 2001, Seminars in urologic oncology,
Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
January 2017, Oncoimmunology,
Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
November 2022, Asian Pacific journal of cancer prevention : APJCP,
Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
February 2009, European urology,
Lin Zhou, and Le Xu, and Lingli Chen, and Qiang Fu, and Zheng Liu, and Yuan Chang, and Zongming Lin, and Jiejie Xu
January 2021, Translational andrology and urology,
Copied contents to your clipboard!